Purpose of study
================

Until recently, few prospective data existed to indicate safety/efficacy of NVP with entry CD4 count restricted to \<250 (women) or \<400 (men) cells/mm^3^. Two phase IV trials, ARTEN and NEWART, compared virologic safety/efficacy of NVP vs ATV/r on a background of TDF/FTC in HIV+ patients within these CD4 ranges. NEWART (US) was designed to be confirmatory of ARTEN and to supplement ARTEN data \[[@B1]\].

Methods
=======

In NEWART, treatment naïve patients were randomized to open-label NVP 200mg BID (lead-in dose 200mg QD x 14 days) or ATV/r (300/100mg) plus TDF/FTC (300/200mg). Women had CD4 counts (cells/mm3) \<250; men \<400. Primary endpoint was virologic response prior to and at week 48 defined as confirmed HIV viral load (VL) \<50 copies/mL without subsequent rebound or therapy change. A point estimate of -6.5% or higher for difference in proportion of responders (NVP-ATV/r) was considered consistent with a successful ARTEN study.

Summary of results
==================

152 patients were treated: 89% male, 68% White, 31% Black. At baseline, mean log10 VL was 4.9 and median CD4 count (cells/mm3) was 176 (NVP) and 193 (ATV/r). Table [1](#T1){ref-type="table"} summarizes key outcome measures. Mean plasma lipid (mg/dL) changes from baseline through 48 weeks (last observation carried forward) were as follows (NVP and ATV/r arms, respectively): total cholesterol (TC) 18.2 and 13.8 (P=0.73); HDL cholesterol (HDLc) 9.6 and 3.5 (P=0.016); LDL cholesterol (LDLc) 8.7 and 6.9 (P=0.93); and triglycerides -4.7 and 8.4 (P=0.36).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome Measure (48 wks)                                NVP 200 mg BID (n=75)   ATV/r 300/100 QD (n=77)   P value   Difference (95% CI) from model\
                                                                                                                      adjusting for screening VL and CD4+
  ------------------------------------------------------- ----------------------- ------------------------- --------- -------------------------------------
  Virologic Response (VR)                                 46 (61.3%)              50 (64.9%)                0.71      -4.1% (-18.3% to 10.1%)

                                                                                                                      

  Virologic Failure (VF), Protocol Defined                10 (13.3%)              12 (15.6%)                0.63      -2.6% (-13.1% to 7.9%)

                                                                                                                      

  Early withdrawals†                                      24                      18                                  

                                                                                                                      

  \- due to investigator-defined VF                       5                       0                                   

                                                                                                                      

  \- due to adverse events                                9\*                     9                                   

                                                                                                                      

  \- due to other reason                                  10                      9                                   

                                                                                                                      

  Mean Change in TC/HDLc \[baseline to week 48 (LOCF)\]   -0.38                   -0.02                     0.038     -0.33 (-0.64 to -0.02)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

\*NVP arm: 1 DAIDS grade 3 hepatobiliary AE (viral hepatitis); no grade 3/4 rash †2 deaths: 1-NVP (suicide); 1-ATV/r (lymphoma)

For NEWART and ARTEN (combined), VR for NVP 200mg BID was 65% (171/263) vs 65% for ATV/r (176/270) \[P=0.75 (CI= -7.7% to 10.7%)\].

Conclusions
===========

NVP + TDF/FTC was noninferior to ATV/r + TDF/FTC. Although trial discontinuations were greater in the NVP arm, VR was similar because of less documented VF. HDLc increased and TC/HDLc decreased significantly more for NVP than for ATV/r.
